Literature DB >> 3691605

The relationship between the QT interval and plasma amiodarone concentration in patients on long-term therapy.

C D Burgess1, R W Siebers, G L Purdie, C Taylor, T J Maling.   

Abstract

We have studied 27 patients on long-term treatment (6-60 months) with amiodarone (dose range 350 mg per week to 2800 mg per week) to ascertain whether the corrected QT interval could predict plasma amiodarone or plasma desethylamiodarone concentration. The patients were assessed on three or four occasions one month apart. There were positive correlations for delta % QTc and plasma amiodarone and delta % QTc and plasma desethylamiodarone. There was approximately a four-fold variation for delta % QTc and plasma amiodarone. This variation was not accounted for by between-occasion variation in the QTc interval, as the coefficient of variation was 2.1%. In six of the patients delta % QTc either decreased or did not change. delta % QTc is not a reliable predictor of plasma amiodarone concentration in the individual patient over time.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691605     DOI: 10.1007/bf00544553

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Amiodarone and the thyroid.

Authors:  M D Gammage; J A Franklyn
Journal:  Br J Clin Pract Suppl       Date:  1986-04

2.  Side effects and complications of amiodarone therapy.

Authors:  E A Raeder; P J Podrid; B Lown
Journal:  Am Heart J       Date:  1985-05       Impact factor: 4.749

3.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Effects of amiodarone on thyroid function in patients with ischaemic heart disease.

Authors:  D A Pritchard; B N Singh; P J Hurley
Journal:  Br Heart J       Date:  1975-08

5.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

6.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

7.  Plasma and red blood cell concentrations of amiodarone during chronic therapy.

Authors:  J J Heger; E B Solow; E N Prystowsky; D P Zipes
Journal:  Am J Cardiol       Date:  1984-03-15       Impact factor: 2.778

8.  The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone.

Authors:  N M Debbas; C du Cailar; R S Bexton; J G Demaille; A J Camm; P Puech
Journal:  Br Heart J       Date:  1984-03

Review 9.  Amiodarone: historical development and pharmacologic profile.

Authors:  B N Singh
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

  9 in total
  3 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Amiodarone therapeutic plasma concentration monitoring. Is it practical?

Authors:  T Maling
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

3.  QT interval dispersion analysis in patients undergoing left partial ventriculectomy (Batista operation).

Authors:  Carlos Alberto Pastore; Sandra Regina Arcêncio; Nancy M M O Tobias; Elisabeth Kaiser; Martino Martinelli Filho; Luis Felipe P Moreira; Noedir A Stolf; Edimar Bocchi; José Antonio Franchini Ramires
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.